Get the Stockscreener App
99.78
3.28%
-3.38
After Hours:
99.48
-0.30
-0.30%
Rhythm Pharmaceuticals Inc stock is traded at $99.78, with a volume of 641.65K.
It is down -3.28% in the last 24 hours and down -2.74% over the past month.
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. It is engaged in the development and commercialization of therapies for patients with rare diseases. The company is focused on its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. Geographically the company generates its revenue from the United States and internationally with the majority being generated from the United States.
See More
Previous Close:
$103.16
Open:
$102.95
24h Volume:
641.65K
Relative Volume:
0.86
Market Cap:
$6.66B
Revenue:
$136.86M
Net Income/Loss:
$-168.69M
P/E Ratio:
-35.51
EPS:
-2.81
Net Cash Flow:
$-113.49M
1W Performance:
+1.74%
1M Performance:
-2.74%
6M Performance:
+1.09%
1Y Performance:
+72.81%
1-Day Range:
$97.15
$103.52
1-Week Range:
$97.15
$104.50
52-Week Range:
$45.91
$122.20
Rhythm Pharmaceuticals Inc Stock (RYTM) Company Profile
Name
Rhythm Pharmaceuticals Inc
Sector
Industry
Phone
857-264-4280
Address
222 BERKELEY STREET, BOSTON, MA
Compare RYTM vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RYTM
Rhythm Pharmaceuticals Inc
|
99.78 | 6.88B | 136.86M | -168.69M | -113.49M | -2.81 |
|
VRTX
Vertex Pharmaceuticals Inc
|
476.90 | 119.21B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
779.67 | 82.71B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
844.41 | 52.43B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
336.19 | 45.01B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
362.14 | 39.23B | 4.98B | 69.60M | 525.67M | 0.5198 |
Rhythm Pharmaceuticals Inc Stock (RYTM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-25-25 | Initiated | Citigroup | Buy |
| Nov-05-25 | Downgrade | Oppenheimer | Outperform → Perform |
| Jul-10-25 | Initiated | Goldman | Buy |
| Jul-07-25 | Initiated | Leerink Partners | Outperform |
| Apr-07-25 | Upgrade | BofA Securities | Neutral → Buy |
| Mar-05-25 | Resumed | Stifel | Buy |
| Jan-02-25 | Initiated | Jefferies | Buy |
| Dec-20-24 | Initiated | Oppenheimer | Outperform |
| Oct-21-24 | Initiated | Guggenheim | Buy |
| Sep-18-24 | Initiated | H.C. Wainwright | Buy |
| Sep-17-24 | Initiated | JMP Securities | Mkt Outperform |
| May-08-24 | Downgrade | BofA Securities | Buy → Neutral |
| Dec-19-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Aug-01-23 | Upgrade | BofA Securities | Neutral → Buy |
| Jan-18-23 | Resumed | Canaccord Genuity | Buy |
| Aug-08-22 | Upgrade | Goldman | Neutral → Buy |
| Aug-05-22 | Upgrade | BofA Securities | Underperform → Neutral |
| Jun-17-22 | Reiterated | Needham | Buy |
| Mar-02-22 | Resumed | Stifel | Buy |
| Feb-17-22 | Upgrade | Ladenburg Thalmann | Neutral → Buy |
| Dec-08-21 | Initiated | Wells Fargo | Overweight |
| Nov-19-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Sep-14-21 | Resumed | Goldman | Neutral |
| Aug-04-21 | Downgrade | BofA Securities | Neutral → Underperform |
| Aug-04-21 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Nov-30-20 | Downgrade | BofA Securities | Buy → Neutral |
| Jan-08-20 | Initiated | Goldman | Sell |
| Jul-12-19 | Upgrade | Stifel | Hold → Buy |
| Jul-08-19 | Initiated | Canaccord Genuity | Buy |
| Mar-13-19 | Initiated | Ladenburg Thalmann | Buy |
| Sep-07-18 | Resumed | Morgan Stanley | Overweight |
| Jun-25-18 | Reiterated | Needham | Buy |
| Jun-15-18 | Reiterated | Needham | Buy |
| Oct-30-17 | Initiated | BofA/Merrill | Buy |
| Oct-30-17 | Initiated | Needham | Buy |
View All
Rhythm Pharmaceuticals Inc Stock (RYTM) Latest News
Is Rhythm Pharmaceuticals Inc vulnerable to short sellersWeekly Trade Summary & Weekly High Return Opportunities - baoquankhu1.vn
Royal Bank Of Canada Upgrades Rhythm Pharmaceuticals (NASDAQ:RYTM) to Moderate Buy - MarketBeat
Rhythm Pharmaceuticals (NASDAQ:RYTM) CFO Hunter Smith Sells 3,569 Shares - MarketBeat
Insider Sell: Hunter Smith Sells Shares of Rhythm Pharmaceuticals Inc (RYTM) - GuruFocus
Rhythm pharmaceuticals CFO Smith sells $805k in shares - Investing.com Nigeria
Rhythm pharmaceuticals CFO Smith sells $805k in shares By Investing.com - Investing.com Canada
Expert Outlook: Rhythm Pharmaceuticals Through The Eyes Of 11 Analysts - Benzinga
Rhythm Pharmaceuticals Is Well-Positioned, Analyst Says Could Capture Big Share Of Rare Obesity Market - Benzinga
Rhythm Pharmaceuticals Seen Poised for Growth in Rare Genetic Obesity, RBC Says - marketscreener.com
RBC Capital Initiates Coverage on Rhythm Pharmaceuticals With OutperformSpeculative Risk Rating, $145 Price Target - marketscreener.com
Rhythm Pharmaceuticals, Inc. (RYTM) Expected to Beat Earnings Estimates: Should You Buy? - Finviz
RBC Capital Initiates Coverage on RYTM with 'Outperform' Rating - GuruFocus
RBC Capital Initiates Coverage of Rhythm Pharmaceuticals (RYTM) with Outperform Recommendation - Nasdaq
Rhythm Pharmaceuticals (NASDAQ:RYTM) Upgraded by Zacks Research to Hold Rating - MarketBeat
Readystate Asset Management LP Sells 16,301 Shares of Rhythm Pharmaceuticals, Inc. $RYTM - MarketBeat
RBC Capital initiates Rhythm Pharmaceuticals stock with outperform rating - Investing.com
How The Rhythm Pharmaceuticals RYTM Story Is Shifting With Imcivree Revenue And New Targets - Yahoo Finance
Rhythm Pharmaceuticals (RYTM) to Release Quarterly Earnings on Wednesday - MarketBeat
IPO Launch: Can Rhythm Pharmaceuticals Inc expand into new marketsJuly 2025 Momentum & Technical Confirmation Alerts - baoquankhu1.vn
Rhythm Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, February 26, 2026 - The Manila Times
Rhythm Pharmaceuticals to Report Fourth Quarter and Full - GlobeNewswire
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Rhythm Pharma label expansion requests for obesity drug undergo U.S. EU reviews - MSN
Rhythm Pharmaceuticals, Inc. (RYTM) Stock Analysis: A 44% Upside Potential in the Biotech Space - DirectorsTalk Interviews
Trading Systems Reacting to (RYTM) Volatility - Stock Traders Daily
Rhythm Pharmaceuticals Eyes March 20 HO PDUFA, Highlights IMCIVREE Growth at Guggenheim Conf. - MarketBeat
Will Rhythm Pharmaceuticals Inc. stock remain a Wall Street favoriteJuly 2025 Big Picture & Daily Technical Stock Forecast Reports - mfd.ru
Assessing Rhythm Pharmaceuticals (RYTM) Valuation After Recent Share Price Weakness - Sahm
Rhythm Pharmaceuticals (NASDAQ:RYTM) CFO Sells $272,755.26 in Stock - MarketBeat
Hunter Smith Sells 2,713 Shares of Rhythm Pharmaceuticals (NASDAQ:RYTM) Stock - MarketBeat
Rhythm’s LB54640 Trial Completion Sets Up Key Catalyst in Hypothalamic Obesity - TipRanks
Jobs Data: Is Atossa Therapeutics Incs growth already priced inJuly 2025 Price Swings & Stepwise Swing Trade Plans - baoquankhu1.vn
Rhythm Pharmaceuticals at Guggenheim Summit: Expanding Horizons in Biotech By Investing.com - Investing.com Canada
Is Rhythm Pharmaceuticals Inc. stock risky to hold now2025 Price Targets & Long-Term Growth Stock Strategies - mfd.ru
Earnings Risk: Is Rhythm Pharmaceuticals Inc currently under institutional pressure2025 Volume Leaders & Low Volatility Stock Suggestions - baoquankhu1.vn
Candriam S.C.A. Lowers Position in Rhythm Pharmaceuticals, Inc. $RYTM - MarketBeat
What are Rhythm Pharmaceuticals Inc.’s recent SEC filings showingChart Signals & Community Consensus Trade Alerts - mfd.ru
Rhythm Pharmaceuticals prices $175M stock offering - MSN
Bond Watch: Will Rhythm Pharmaceuticals Inc benefit from green energy policies2025 Growth vs Value & Short-Term Trading Alerts - baoquankhu1.vn
Smith, Rhythm Pharmaceuticals CFO, sells $702k in RYTM stock - Investing.com Australia
Smith, Rhythm Pharmaceuticals CFO, sells $702k in RYTM stock By Investing.com - Investing.com Canada
Rhythm Pharmaceuticals (NASDAQ:RYTM) CFO Sells $358,588.86 in Stock - MarketBeat
Penserra Capital Management LLC Acquires Shares of 30,436 Rhythm Pharmaceuticals, Inc. $RYTM - MarketBeat
Rhythm Pharmaceuticals' CFO Hunter C. Smith to Speak at Guggenheim Emerging Outlook: Biotech Summit 2026 - Quiver Quantitative
Rhythm Pharmaceuticals Announces Participation in Upcoming Guggenheim Biotech Summit - GlobeNewswire
Rhythm Pharmaceuticals, Inc. $RYTM Shares Acquired by New York State Common Retirement Fund - MarketBeat
How Rhythm Pharmaceuticals Inc. (RYTM) Affects Rotational Strategy Timing - Stock Traders Daily
WCM Investment Management LLC Makes New Investment in Rhythm Pharmaceuticals, Inc. $RYTM - MarketBeat
This High-Flying Growth Stock Is Hiding in Plain Sight - Finviz
Federated Hermes Inc. Has $174.50 Million Position in Rhythm Pharmaceuticals, Inc. $RYTM - MarketBeat
EFG Asset Management North America Corp. Invests $2.05 Million in Rhythm Pharmaceuticals, Inc. $RYTM - MarketBeat
Rhythm Pharmaceuticals Inc Stock (RYTM) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.34%
0.89%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):